Capital Advisors Ltd’s TherapeuticsMD TXMD Stock Holding History

Capital Advisors Ltd’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-66	Closed	-$1K	–	1528
2022 Q2	$1K	Buy	+66	New	+$630	﹤0.01%	906

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Capital Advisors Ltd's TXMD Position: Q3 2022 in Review

Capital Advisors Ltd sold out of TherapeuticsMD (TXMD) in Q3 2022, closing a stake of 66 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in TXMD in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 43 funds tracked by Wall St. Rank hold TXMD as of Q3 2022.

Capital Advisors Ltd reported no remaining TherapeuticsMD position as of Q3 2022 after selling out during the quarter.
Capital Advisors Ltd sold 66 TherapeuticsMD shares in Q3 2022, an estimated $1K.
Capital Advisors Ltd first reported a position in TherapeuticsMD in Q2 2022 and held it in 1 quarter.
Capital Advisors Ltd's TherapeuticsMD position peaked at $1K in Q2 2022.
43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.